Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 3.00% is 33% below its 5-year average of 4.45%, near the low end of its 5-year range (1.81%–9.09%).
As of the fiscal period ended Tuesday, June 30, 2026. 15.35% above its 12-month average of 2.60%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 3.00%.
DEBT TO ASSETS RATIO
3.00%
DEBT TO ASSETS RATIO AVG TTM
2.60%
DEBT TO ASSETS RATIO AVG 3Y
2.54%
DEBT TO ASSETS RATIO AVG 5Y
4.45%
DEBT TO ASSETS RATIO AVG 10Y
4.54%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+15.35%
CURRENT VS 3Y AVG
+18.17%
CURRENT VS 5Y AVG
-32.61%
CURRENT VS 10Y AVG
-33.96%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 592 covered companies
CURRENT VS SECTOR MEDIAN
+2898.15%
vs the sector median at left
Larimar Therapeutics, Inc.
Market Cap
$286.20M
Debt to Assets Ratio
3.00%
TTM Avg
2.60%
3Y Avg
2.54%
5Y Avg
4.45%
Market Cap
$284.38M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$282.98M
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$281.92M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$276.57M
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$297.18M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$274.61M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$272.17M
Debt to Assets Ratio
0.29%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$305.73M
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Larimar Therapeutics, Inc. (LRMR) | $286.20M | 3.00% | 2.60% | 2.54% | 4.45% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $284.38M | 0.01% | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $282.98M | 0.11% | N/A | N/A | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.92M | 0.02% | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $276.57M | 0.04% | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $297.18M | 0.00% | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $274.61M | 0.00% | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $272.17M | 0.29% | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $305.73M | 0.04% | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.16M | 0.01% | N/A | N/A | N/A |
Debt/Assets
3.0%
Debt/Equity
0.04
Current Ratio
4.70
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 3.00% |
| 2026-03-31 | 1.81% |
| 2025-12-31 | 2.79% |
| 2025-09-30 | 2.32% |
| 2025-06-30 | 3.08% |
| 2025-03-31 | 2.86% |
| 2024-12-31 | 2.56% |
| 2024-09-30 | 2.45% |
| 2024-06-30 | 2.36% |
| 2024-03-31 | 2.15% |
| 2023-12-31 | 5.78% |
| 2023-09-30 | 5.19% |
| 2023-06-30 | 4.54% |
| 2023-03-31 | 4.41% |
| 2022-12-31 | 4.28% |
| 2022-09-30 | 4.18% |
| 2022-06-30 | 9.09% |
| 2022-03-31 | 8.23% |
| 2021-12-31 | 7.63% |
| 2021-09-30 | 6.98% |
| 2021-06-30 | 7.74% |
| 2021-03-31 | 6.87% |
| 2020-12-31 | 6.23% |
| 2020-09-30 | 5.85% |
| 2020-06-30 | 5.47% |
| 2020-03-31 | 28.19% |
| 2019-12-31 | 1.87% |
| 2019-09-30 | 18.77% |
| 2019-06-30 | 18.41% |
| 2019-03-31 | 18.88% |
| 2018-12-31 | 16.95% |
| 2018-09-30 | 15.52% |
| 2018-06-30 | 25.46% |
| 2018-03-31 | 21.77% |
| 2017-12-31 | 18.96% |
| 2017-09-30 | 1.32% |
| 2017-06-30 | 1.90% |
| 2017-03-31 | 2.38% |
| 2016-12-31 | 2.73% |
| 2016-09-30 | 3.03% |
| 2016-06-30 | 3.25% |
| 2016-03-31 | 3.36% |
| 2015-12-31 | 3.38% |
| 2015-09-30 | 3.39% |
| 2015-06-30 | 3.45% |
| 2015-03-31 | 3.22% |
| 2014-12-31 | 6.43% |
| 2014-09-30 | 5.79% |
| 2014-06-30 | 5.44% |
